392 A phase 1a/b study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally dvanced or metastatic solid tumors and urothelial carcinoma

• Jason Luke,
• Meredith McKean,
• Nehal Lakhani,
• Katherine Kacena,
• Alan Tan,
• Babar Bashir,
• David Aggen,
• Marissa Timothy,
• Sergio Santillana

Affiliations

Jason Luke

1University of Iowa, Iowa City, IA, USA

Meredith McKean

Aff6 0000 0001 2291 4776grid.240145.6Division of Cancer MedicineUniversity of Texas MD Anderson Cancer Center 77030 Houston TX USA

Nehal Lakhani

4START Midwest, Grand Rapids, MI, USA

Katherine Kacena

BioBridges, Wellesley, Massachusetts, USA

Alan Tan

2Rush University Medical Center, Chicago, IL, USA

Babar Bashir

4Thomas Jefferson University, Philadelphia, PA, USA

David Aggen

5Memorial Sloan Kettering Cancer Center, New York, NY, USA

Marissa Timothy

8Ikena Oncology, Boston, MA, USA

Sergio Santillana

8Ikena Oncology, Boston, MA, USA